Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane-Reference-Cited by-同舟云学术

Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane

Published:2023-07-28 Issue:10 Volume:70 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Mavinkurve‐Groothuis Annelies M. C.¹^ORCID,de Baat Esmee C.¹^ORCID,Feijen Elizabeth A. M.¹^ORCID,Kremer Leontien C. M.¹²³,Armenian Saro H.⁴^ORCID,Mulder Renee L.¹,van Dalen Elvira C.¹

Affiliation:

1. Princess Máxima Center for Pediatric Oncology Utrecht Netherlands

2. Department of Pediatric Cardiology, Wilhelmina Children's Hospital University Medical Center Utrecht Utrecht Netherlands

3. Emma Children's Hospital Amsterdam UMC University of Amsterdam Amsterdam Netherlands

4. Population Sciences City of Hope National Medical Center Duarte California USA

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.30604

Reference4 articles.

1. Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane

2. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines;Baat EC;Cochrane Database Syst Rev,2022

3. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group

4. Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane;Pediatric Blood & Cancer;2023-09-22